Clinical Outcomes and Their Prognostic Factors among Cervical Cancer Patients with Bone Recurrence

Table 2

Univariable clinical prognostic factors for overall survival.

Factor	n	Median (months) (95% CI)	-Value
Age at diagnosis of bone recurrence (years)
<60	68	5 (3-7)	0.001
≥60	30	11 (5-26)
FIGO (2009)
I	10	5 (0-100)	0.031
II	39	5 (3-7)
III	42	7 (4-9)
IV	7	35 (1-100)
Histopathologic diagnosis
Squamous cell carcinoma	81	7 (5-8)	0.132
Adenocarcinoma	11	3 (2-7)
Adenosquamous carcinoma	3	3 (1-100)
Other	3	3 (1-100)
Primary treatment
Radiation	43	5 (3-8)	0.517
Concurrent chemoradiation	47	6 (4-7)
Surgery	8	7 (3-100)
Symptoms
No	5	2 (1-100)	0.003
Yes	93	6 (4-9)
Time to bone recurrence
<21 months	47	3 (2-6)	0.104
≥21 months	51	7 (5-9)
Tumor spread
Solitary	61	6 (5-7)	0.765
Multiple	37	5 (3-9)
Sites of bone recurrence
Pelvis	12	7 (5-9)	0.424
Nonpelvis	72	5 (3-7)
Both	14	5 (2-9)
Coexisting recurrence
No	42	6 (4-11)	0.357
Yes	56	6 (4-7)
Treatment of bone recurrence
Radiation	54	6 (3-7)
Chemotherapy	7	6 (2-8)
Radiation-chemotherapy	14	10 (4-15)
Supportive care	20	4 (1-10)
Surgery radiation chemotherapy	3	4 (1-100)	0.090
Leukocyte count (μL)
<10000	29	7 (5-9)	0.001
≥10000	69	3(2-5)
Hemoglobin (g/dL)
<11	42	5 (4-7)	0.171
≥11	56	7 (4-11)
Platelet count (μL)
<400000	32	7 (5-9)	0.002
≥400000	66	3 (2-6)

CI, confidence interval; FIGO stage, International Federation of Gynecology and Obstetrics Staging System 2009.